Article Text

Download PDFPDF

2022-RA-1502-ESGO Multiplexed biomarker detection using the QuantiGene assay in women living with HIV for cervical dysplasia detection
  1. Anna Sophie Skof1,
  2. Wilbert Mbuya2,
  3. Ruby Mcharo2,
  4. Liset Torres2,
  5. John France3,
  6. Arne Kroidl4,
  7. Christof Geldmacher4 and
  8. Andreas M Kaufmann1
  1. 1Department of Gynaecology, Charité – Universitätsmedizin Berlin – corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
  2. 2Mbeya Medical Research Center (MMRC), National Institute for Medical Research (NIMR), Mbeya, Tanzania, United Republic of
  3. 3Mbeya Referral Hospital (MRH), Mbeya, Tanzania, United Republic of
  4. 4Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany


Introduction/Background Cervical cancer (CxCa) and its precursor lesions are caused by persistent infection with a high-risk(HR) Human Papillomavirus (HPV). Women living with HIV (WLWH) have a higher risk for cervical dysplasia and CxCa development. The high HPV prevalence in WLWH makes a HPV-PCR based screening non-efficient. Biomarker detection could be a possibility, to find woman at risk. We evaluated the biomarker-based QuantiGene-Molecular-Profiling-Histology assay (QG-MPH) in WLWH.

Methodology We analysed a representative subset of samples (n=301) from the prospective 2H-study including HIV+ and HIV- women. A cervical sample was collected using a cytobrush and fixed into ThinPrep/PreservCyt. The QG-MPH assay is based on the multiplexed Luminex bead-based technology platform (QuantiGene 2.0). It detects and quantifies the mRNA of 18 HR-HPV genotype-specific oncogenes, reference genes and cellular biomarkers including proliferation, tumour stem cell and tumour markers to predict the dysplasia stage, simultaneously.

Results HIV coinfection was significantly associated with increased mRNA expression of the following biomarkers in HR-HPV+ women without cervical lesions: leading HPV-E7 (p=0.0019), p16 (p=0.022), STMN1 (p=0.0039), MCM2 (p=0.015), KRT7 (p=0.0035) and KRT17 (p=0.014). In cervical cancer cases (HIV+=19, HIV-=18) only the expression of Nanog mRNA was different (p=0.022). Using the risk score developed on a HIV- cohort led to false positive detection (CIN3+) of 68.8% (n=22) in WLWH without lesions. Logistic regression analyses showed best markers for CxCa detection in HIV+ patients in our cohort were BIRC5, KRT17, MMP7 and p53 with a combined AUC of 0.93 (sensitivity=95%, specificity=82.0%).

Conclusion Viral oncogene expression is increased in HR-HPV+ WLWH without cervical lesions. Biomarker evaluation has the potential to overcome problems of HPV PCR-based screening in WLWH. However, risk score adaptation is needed as biomarker expression varies between HIV+ and HIV- patients. Further studies with higher sample number are warranted to confirm the best markers and risk scores by QG-MPH analysis.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.